CDER Medical Policy Council Balances “Breakthrough” Requests With Broader Issues
Executive Summary
FDA is seeking public input on cross-cutting policy issues to bring before the senior-level group, which is also facing the challenge of reviewing dozens of “breakthrough therapy” designation requests relevant to CDER-regulated products.
You may also be interested in...
Breakthrough Designation Can Be 'Lever' For Manufacturing Evolution, FDA Says
CDER Director Woodcock notes breakthrough program often pushes sponsors to modernize production processes.
FDA Central Review Likely For Novel Surrogate Endpoints
CDER’s Woodcock says accelerated approval requirements in 21st Century Cures legislation could create a process akin to how FDA handles breakthrough designations.
Inside FDA’s Debates On ‘Breakthrough’
Office of New Drugs Director Jenkins provides a peek into the Medical Policy Council’s efforts to consistently interpret and implement the ‘breakthrough therapy’ program.